How can life sciences and chemical manufacturers move AI initiatives from experimentation to measurable business value at scale? Our manufacturing AI blueprint provides a visual outline of the stages of AI adoption, key indicators of success, and common challenges manufacturers face when moving AI capabilities from initial pilot projects into daily use and broader deployment with scalable operational value. Download the guide below, and continue reading for more on the topic of AI maturity in life sciences and chemical manufacturing.

Download the Blueprint for Scaling AI in Manufacturing Here

An AI demo can generate excitement about what a tool could do, and a pilot can demonstrate how it works in an isolated area. But showing an operational benefit at scale requires a closer look at how the insight becomes part of daily work.  

A useful recommendation needs to reach someone who can interpret it and take authorized action before production is affected. For life sciences and chemical manufacturers, that means connecting operational data with the engineering knowledge needed to interpret it.  

The resulting recommendations need a place within approved workflows, where people have clear authority to act. Designing those connections during the pilot helps teams assess whether the capability can improve daily work and what it would take to sustain that improvement across sites. 

Start With the Operating Decision 

A useful starting point is a decision that teams struggle to make early enough or consistently enough. For maintenance teams, that might involve identifying an asset that needs attention before the next production run with the intent to reduce unplanned downtime. Quality teams might focus on recognizing recurring issue across batch records to reduce repeat deviations. 

For either use case, teams need to define the action that better information could support and the person responsible for taking it. The intended improvement should also guide how success is measured. For an AI-assisted batch review use case, for example, teams could compare the time needed to complete a review against today’s approach, providing a basis for evaluating the investment’s connection to the operating outcome. Technical accuracy is part of that assessment, as well as evidence that the insight improves a decision. 

An early warning has limited value if no one has time to investigate it. The pilot therefore needs to test whether the organization can respond while the insight is still useful, including any constraints that could prevent action. 

Connect Operational Data with the Knowledge to Interpret It 

Plant data becomes more useful when teams can relate it to the conditions under which it was generated. Because a temperature reading may carry a different meaning during startup than during steady production, its interpretation depends on knowing the operating state. Similarly, lab results may need to be considered alongside batch history or a recent equipment intervention. 

Engineering knowledge helps teams judge whether an AI recommendation applies to the current situation, while approved procedures and operating limits establish the boundaries for an appropriate response. Supporting those connections requires data governance that establishes consistent definitions and clear ownership. In drug manufacturing, these practices should also align with the FDA’s data integrity guidance. 

When teams can trace an output to its inputs, they’re better able to investigate whether an apparent model problem originates in missing information or inconsistent source data. Treating that context as a shared asset also gives later use cases a foundation to reuse. 

Make the Capability Part of How Work Gets Done 

Adoption should be designed into the use case from the beginning, with change management involved while the workflow is taking shape. Treating adoption as a handoff once the technology is complete can leave important operating decisions unresolved. Those early discussions should establish when a recommendation reaches the user and what happens after it’s reviewed. If action requires another function’s approval, that dependency should be part of the design. 

When an equipment warning arrives during production planning, for example, the workflow needs to allow time for maintenance personnel to investigate it. Operations must also understand how a proposed intervention would affect current production commitments. The people doing the work can help determine whether that response is practical and whether the information arrives at a useful point. Their involvement during design can also inform training that explains the capability’s limitations. 

For chemical and life sciences manufacturers, adoption becomes visible when the tool is part of how work gets done. Login activity may show that people are accessing it, while changes in decisions provide a better basis for assessing its operational value.  

Once the capability is in use, assess how it affects the intended decision and whether the resulting change improves performance. User feedback can help explain where the workflow needs adjustment, with updates introduced through the appropriate change process. 

Put Human Authority and Guardrails in Place 

Trust depends in part on knowing what the capability is intended to support and where its limits lie. A human-in-the-loop framework can make those boundaries practical by defining who receives an insight and who can authorize a response. Security and access controls should reflect those responsibilities, with additional review for decisions that carry greater risk. The voluntary NIST AI Risk Management Framework provides a reference for defining human oversight and monitoring responsibilities. 

Agreed risk tolerances should help determine when a recommendation requires further investigation and which specialists need to be involved. Users also need to know when they can rely on an output and when they should override a recommendation. If an output conflicts with approved procedures or process knowledge, a clear escalation path should identify who can reject it and who approves the next step. 

For life sciences manufacturers, validation and model changes need quality oversight that reflects the intended GxP use and associated risk. In its 2023 discussion paper on AI in drug manufacturing, the FDA identifies model validation and lifecycle changes as areas for further regulatory consideration. Chemical manufacturers should assess recommendations against established operating limits and site safety requirements. Applicable changes to processes covered by OSHA’s Process Safety Management standard must also follow procedure. 

Monitoring should help teams recognize when inputs become unreliable or the capability’s performance changes. Defined responses give people a basis for using AI within their authority along with a way to continue work safely when the capability is unavailable. 

Five Questions to Ask Before Investing 

These considerations can help leaders evaluate which use cases are ready for investment and where additional preparation is needed. 

1. Material outcome: What measurable operating improvement would justify the investment? Who will receive the insight, and what could they do differently? Can they act early enough to change the operating outcome? 
2. Accountable owner: Is there a process owner with the authority to change the work and sustain the new workflow? 
3. Trusted context: Does the use case connect reliable data with relevant process knowledge? Are the relationships and controls needed to interpret its output in place? 
4. Human authority and control: Do users understand when they can rely on a recommendation or need further investigation? Who can authorize action or reject the recommendation?
5. Reusable capability and scale: Can the resulting data model or workflow extend across sites or functions? What needs local assessment before it can be reused? 

Download our supplemental manufacturing AI blueprint to use this readiness checklist alongside a visual guide to progressing from pilot to scale. 

Prioritize Investments by Capability 

AI maturity should be assessed at the capability level. A manufacturer may be ready to extend a maintenance application while a quality use case still needs to demonstrate value within its first workflow. That distinction helps leaders direct investment toward the work each capability needs next. 

Once a capability improves a decision in daily use, assess what another site can reuse. Common data definitions or workflow components may reduce repeat work, while differences in equipment and operating practices may require local testing or adaptation. 

A useful next step is to select a focused set of investments and define what each should demonstrate in roughly 90 days. Depending on readiness, that might mean showing a measurable workflow benefit or establishing the data foundation needed to test it. The resulting evidence can help manufacturers decide where to expand, with a clearer understanding of the controls and support needed to sustain performance. 

Learn more about our AI Consulting Services 

Download the Blueprint for Scaling AI in Manufacturing guide.